SAPHRIS + Asenapine
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Bipolar Disorder
Trial Timeline
Jul 1, 2013 → Aug 1, 2013
NCT ID
NCT01948024About SAPHRIS + Asenapine
SAPHRIS + Asenapine is a phase 1 stage product being developed by Sun Pharmaceutical for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01948024. Target conditions include Schizophrenia, Bipolar Disorder.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01948024 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia